PCM
IART icon

Penn Capital Management’s Integra LifeSciences IART Stock Holding History

Penn Capital Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-118,888
Closed -$2.16M – 157
2024
Q3 		$2.16M Buy
+118,888
New +$2.76M 0.2% 101

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Penn Capital Management's IART Position: Q4 2024 in Review

Penn Capital Management sold out of Integra LifeSciences (IART) in Q4 2024, closing a stake of 118,888 shares — an estimated $2.16M sold.

Penn Capital Management first reported a position in IART in Q3 2024 and held it in 1 quarter. The position peaked at $2.16M in Q3 2024. 223 funds tracked by Wall St. Rank hold IART as of Q4 2024.

  • Penn Capital Management reported no remaining Integra LifeSciences position as of Q4 2024 after selling out during the quarter.
  • Penn Capital Management sold 118,888 Integra LifeSciences shares in Q4 2024, an estimated $2.16M.
  • Penn Capital Management first reported a position in Integra LifeSciences in Q3 2024 and held it in 1 quarter.
  • Penn Capital Management's Integra LifeSciences position peaked at $2.16M in Q3 2024.
  • 223 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2024.

Based on Penn Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.